Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious 2015 ... flagship nutritional supplement, Liquid BioCell™ Life, and the relaunch ... logo, new packaging, new products, and new messaging. ... and promote programs that serve as examples of direct ... International for their outstanding accomplishments and contributions to direct ...
(Date:5/1/2015)... NJ (PRWEB) May 01, 2015 Hope ... continued support of Hope For The Warriors® and military ... $20K to support Hope For The Warriors®, a national ... the family unit, and restoring hope for our service ... autograph signings, All American Ford collected and matched small ...
Breaking Medicine News(10 mins):Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... five whites could carry a genetic variant that substantially increases ... to new research. This genetic variant, characterized by one ... response to specific chemical signals. In the study, led by ... more than threefold increase in the odds that carriers will ...
... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) -- New research ... -- contain a fatty acid that may lower the risk of ... according to the study in the Dec. 21 issue of the ... blood levels of this fatty acid reduce their odds of diabetes ...
... TUESDAY, Dec. 21 (HealthDay News) -- Judy Brown says she has ... Brown, now 51 and living in Nashua, N.H., remembers being ... come on, even though she didn,t understand at the time what ... she said. "Sometimes it would be a car, a back seat ...
... people with early stage liver cancer were more likely than ... new study from the University of Michigan Comprehensive Cancer Center. ... cancer patients were alive but only 15 percent of Hispanic ... times ranged from 10 months for whites and Hispanics to ...
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... among Americans, a new study shows, despite reported links to ... safe "spray-on" tans. In fact, about one in every ... they use indoor tanning, University of Minnesota researchers report. ...
Cached Medicine News:Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 2Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 3Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 4Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 2Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 3Health News:A Lifetime of Migraines 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3
... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Medicine Products: